Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069878 | 0.95 | CHRNA7 (0.49) | CHRNA7HTR2CGRIN2BGRIN1CYP19A1 | |
| SCHEMBL607389 | 0.90 | CYP19A1 (0.52) | CHRNA7HTR2CGRIN2BGRIN1CYP19A1 | |
| SCHEMBL1478135 | 0.87 | MTNR1B (0.51) | CHRNA7GID4HTR2CSIGMAR1 | |
| SCHEMBL6797543 | 0.87 | MTNR1B (0.51) | CHRNA7GID4HTR2CSIGMAR1 | |
| SCHEMBL6805525 | 0.87 | MTNR1B (0.51) | CHRNA7GID4HTR2CSIGMAR1 | |
| SCHEMBL5444335 | 0.85 | PGR (0.48) | GID4HTR2CSIGMAR1 | |
| SCHEMBL31650156 | 0.81 | HTR2C (0.60) | CHRNA7GID4HTR2CSIGMAR1CYP19A1 | |
| SCHEMBL13273185 | 0.81 | HTR2C (0.60) | CHRNA7GID4HTR2CSIGMAR1CYP19A1 | |
| SCHEMBL8983524 | 0.81 | HTR2C (0.60) | CHRNA7GID4HTR2CSIGMAR1CYP19A1 | |
| SCHEMBL9221653 | 0.81 | PGR (0.43) | GRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162820-B2 | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2024-12-10 | — | — | US | disclosed |
| CN-113660932-B | Phenyl derivatives having pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2022-05-19 | — | — | US | disclosed |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS CO., LTD. (TW) | 2022-05-19 | — | — | US | disclosed |
| EP-3946299-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | Taiwanj Pharmaceuticals Co., Ltd. (TW) | 2022-02-09 | — | — | EP | disclosed |
| CN-113660932-A | Phenyl derivatives with pendant alkyl and alkenyl extensions and pharmaceutical compositions comprising the same | 景凯生物科技股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| WO-2020205455-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | TAIWANJ PHARMACEUTICALS, CO., LTD. (TW) | 2020-10-08 | — | — | WO | disclosed |
| US-20160083409-A1 | METHOD FOR THE PREPARATION OF alpha-SUBSTITUTED ACRYL ALDEHYDES | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-03-24 | — | — | US | disclosed |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-5756790-A | FROM KETONES | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1998-05-26 | — | — | US | disclosed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| EP-0524517-B1 | Substituted 3,4-dihydronaphthalenes, medicament containing them and process for their preparation | GRUENENTHAL GMBH (DE) | 1995-06-21 | — | — | EP | disclosed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
| US-5254731-A | Enzyme inhibitors; leukotriene disorders | GRUENENTHAL GMBH (DE) | 1993-10-19 | — | — | US | disclosed |
| EP-0524517-A1 | Substituted 3,4-dihydronaphthalenes, medicament containing them and process for their preparation | Grünenthal GmbH (DE) | 1993-01-27 | — | — | EP | disclosed |
| EP-0331511-A1 | 6-Substituted purinyl piperazine derivatives | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| US-4048330-A | Compositions containing 2-(6'-substituted-2'-naphthyl)acetic acid esters used for treating inflammation, pain or pyrexia | SYNTEX CORPORATION (US) | 1977-09-13 | — | — | US | disclosed |
| US-4009197-A | 2-(6-Substituted-2'-naphthyl) acetic acid derivatives and the salts and esters thereof | SYNTEX CORPORATION (PM) | 1977-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | CHRNA7 1571/4885GID4 3685/4885HTR2C 453/4885 |
| US-20220153687-A1 | PERIPHERAL ALKYL AND ALKENYL CHAINS EXTENDED BENZENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME | AADAC, ENPP2, ATXN10 | CHRNA7 670/4885GID4 2441/4885HTR2C 1833/4885 |
| US-20160083409-A1 | METHOD FOR THE PREPARATION OF alpha-SUBSTITUTED ACRYL ALDEHYDES | ALDH1A1, ALDH3A1, ADH1A | CHRNA7 1228/4885GID4 3014/4885HTR2C 2739/4885 |
| US-12162820-B2 | Peripheral alkyl and alkenyl chains extended benzene derivatives and pharmaceutical composition including the same | AADAC, ENPP2, ATXN10 | CHRNA7 670/4885GID4 2441/4885HTR2C 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.